AJANTPHARM - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 4.0
| Stock Code | AJANTPHARM | Market Cap | 36,313 Cr. | Current Price | 2,910 ₹ | High / Low | 3,228 ₹ |
| Stock P/E | 38.5 | Book Value | 330 ₹ | Dividend Yield | 0.97 % | ROCE | 33.0 % |
| ROE | 25.7 % | Face Value | 2.00 ₹ | DMA 50 | 2,838 ₹ | DMA 200 | 2,742 ₹ |
| Chg in FII Hold | 0.29 % | Chg in DII Hold | -0.22 % | PAT Qtr | 245 Cr. | PAT Prev Qtr | 250 Cr. |
| RSI | 57.1 | MACD | -4.14 | Volume | 89,419 | Avg Vol 1Wk | 92,212 |
| Low price | 2,330 ₹ | High price | 3,228 ₹ | PEG Ratio | 4.85 | Debt to equity | 0.01 |
| 52w Index | 64.6 % | Qtr Profit Var | -2.94 % | EPS | 75.5 ₹ | Industry PE | 30.9 |
📊 Analysis: AJANTPHARM demonstrates strong fundamentals with ROCE at 33.0% and ROE at 25.7%, reflecting excellent efficiency and profitability. Debt-to-equity is negligible at 0.01, ensuring financial stability. EPS of 75.5 ₹ supports earnings visibility. However, the P/E ratio of 38.5 is above the industry average of 30.9, and the PEG ratio of 4.85 suggests overvaluation relative to growth. Dividend yield is modest at 0.97%, providing some income support. Quarterly PAT dipped slightly (245 Cr vs 250 Cr), indicating short-term earnings pressure.
💰 Entry Price Zone: Ideal accumulation range is 2,750 ₹ – 2,850 ₹, near the 50 DMA (2,838 ₹) and 200 DMA (2,742 ₹), offering a safer entry below current levels.
📈 Exit Strategy / Holding Period: For existing holders, maintain a long-term horizon (3–5 years) given strong ROE/ROCE and low debt. Consider partial profit booking near 3,150 ₹ – 3,200 ₹ resistance levels. Dividend yield adds modest income, but the main value lies in compounding returns from growth metrics.
✅ Positive
- High ROCE (33.0%) and ROE (25.7%) reflect strong efficiency.
- Debt-to-equity ratio of 0.01 ensures financial stability.
- EPS of 75.5 ₹ supports earnings visibility.
- FII holdings increased (+0.29%), signaling foreign investor confidence.
⚠️ Limitation
- P/E (38.5) above industry average (30.9), limiting upside potential.
- PEG ratio of 4.85 suggests overvaluation relative to growth.
- Quarterly PAT declined slightly (-2.94%).
- DII holdings decreased (-0.22%), showing reduced domestic support.
📉 Company Negative News
- No major negative news reported, but short-term earnings dip is a concern.
📈 Company Positive News
- Strong long-term profitability metrics (ROCE and ROE).
- Stable financial structure with negligible debt.
🏭 Industry
- Industry P/E at 30.9 suggests moderate sector valuation.
- Pharmaceutical sector benefits from consistent demand and innovation-driven growth.
🔎 Conclusion
AJANTPHARM is a fundamentally strong candidate for long-term investment, supported by high ROE/ROCE and negligible debt. Entry near 2,750–2,850 ₹ provides better margin of safety. Hold for 3–5 years to benefit from compounding, but monitor valuation metrics and quarterly earnings. Partial exits near 3,150–3,200 ₹ resistance levels are advisable to lock in gains.